XML 29 R13.htm IDEA: XBRL DOCUMENT v2.4.0.6
AVERAGE SHARE INFORMATION
9 Months Ended
Dec. 31, 2011
AVERAGE SHARE INFORMATION [Abstract]  
AVERAGE SHARE INFORMATION
NOTE 6 – AVERAGE SHARE INFORMATION

The following is a summary of the basic and diluted average common shares outstanding:

   
Three months ended
  
Nine months ended
 
   
December 31,
  
December 31,
 
              
   
2011
  
2010
  
2011
  
2010
 
Basic:
            
Weighted average common shares outstanding (denominator)
  14,747,139   15,704,165   15,046,415   15,828,309 
                  
Diluted:
                
Weighted average common shares outstanding
  14,747,139   15,704,165   15,046,415   15,828,309 
Dilutive potential common shares
  372,540   399,317   395,233   374,924 
Conversion premium on convertible notes
  -   -   11,925   - 
Weighted average diluted shares outstanding (denominator)
  15,119,679   16,103,482   15,453,573   16,203,233 
 
Options to purchase 47,219 and 48,917 shares of common stock at various prices were outstanding during the three months ended December 31, 2011 and 2010, respectively, but were not included in the computation of diluted earnings per share (“EPS”) because the options are anti-dilutive. Options to purchase 16,468 and 21,554 shares of common stock at various prices were outstanding during the nine months ended December 31, 2011 and 2010, respectively, but were not included in the computation of diluted EPS because the options were anti-dilutive.

During the three months and the nine months ended December 31, 2011 and 2010, the warrants related to the convertible notes payable were not included in the computation of dilutive earnings per share because the effect of such instruments was anti-dilutive. The warrants have a strike price of $73.97 and are generally exercisable at any time through February 9, 2012.  The Company issued and sold the warrants in a transaction exempt from the registration requirements of the Securities Act of 1933, as amended, by virtue of section 4(2) thereof.  There were no underwriting commissions or discounts in connection with the sale of the warrants.